Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Novo’s Diabetes Drug Demonstrates Impressive CV Safety Profile

By Ryan Bushey | September 19, 2016

Novo Nordisk’s experimental diabetes drug semaglutide hit an important milestone in a recent study.

The Danish drug maker announced its once-weekly injectable therapy significantly reduced cardiovascular risk by 26 percent in more than 3,000 patients diagnosed with type 2 diabetes, reported Reuters.

Novo previously disclosed in April that the drug was able to lower the risk of cardiovascular events, but this latest notice is the first in which the company revealed the specific numbers related to this effect.

“The reduction in cardiovascular events observed with semaglutide in SUSTAIN 6 is notable given the small study population and the short trial duration,” Dr. Steven Marso, SUSTAIN 6 investigator and the lead author for the New England Journal of Medicine publication of SUSTAIN 6, said in a statement.

Lowering the possibility of cardiovascular events, like heart attack and strokes, is important for type 2 diabetes patients because about half of deaths related to this ailment occur due to heart disease.

Novo did acknowledge in its press release that there was a higher frequency of patients taking semaglutide who experienced complications from diabetic retinopathy, which causes damage to blood vessels at the back of the eye. Also, some participants had to discontinue treatment because of gastrointestinal events.

However, Novo plans to use this data along with an expanded trial exploring the drug’s benefits to make a case for a regulatory submission in the U.S. and Europe during the final quarter of 2016, explained Reuters.

Analysts predict this drug could bring in annual sales of $2.2 billion in 2022.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50